Cancer cell membrane-coated biomimetic platform for tumor targeted photodynamic therapy and hypoxia-amplified bioreductive therapy

Li, Shi‐Ying; Cheng, Hong; Qiu, Wen‐Xiu; Zhang, Lu; Wan, Shuang‐Shuang; Zeng, Jing-Yue; Zhang, Xian‐Zheng

doi:10.1016/j.biomaterials.2017.07.026

Cited by 238 publications

(122 citation statements)

References 42 publications

Supporting

Mentioning

121

Contrasting

Order By: Relevance

“…Tumor hypoxia, a typical feature of tumor microenvironment, is caused by the imbalance between the consumption and supply of O 2 within tumors due to the rapid cell proliferation and abnormal vascular structure . Tumor cells often participate in the expression of hypoxia‐inducible factor 1α (HIF‐1α) protein to adapt to the hypoxic microenvironment .…”

Section: Introductionmentioning

confidence: 99%

A Multifunctional Biomimetic Nanoplatform for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PD‐1/PD‐L1 Axis

Zou

Liu

et al. 2018

Small

Self Cite

134

View full text Add to dashboard Cite

Hypoxia is reported to participate in tumor progression, promote drug resistance, and immune escape within tumor microenvironment, and thus impair therapeutic effects including the chemotherapy and advanced immunotherapy. Here, a multifunctional biomimetic core-shell nanoplatform is reported for improving synergetic chemotherapy and immunotherapy. Based on the properties including good biodegradability and functionalities, the pH-sensitive zeolitic imidazolate framework 8 embedded with catalase and doxorubicin constructs the core and serves as an oxygen generator and drug reservoir. Murine melanoma cell membrane coating on the core provides tumor targeting ability and elicits an immune response due to abundance of antigens. It is demonstrated that this biomimetic core-shell nanoplatform with oxygen generation can be partial to accumulate in tumor and downregulate the expression of hypoxia-inducible factor 1α, which can further enhance the therapeutic effects of chemotherapy and reduce the expression of programmed death ligand 1 (PD-L1). Combined with immune checkpoints blockade therapy by programmed death 1 (PD-1) antibody, the dual inhibition of the PD-1/PD-L1 axis elicits significant immune response and presents a robust effect in lengthening tumor recurrent time and inhibiting tumor metastasis. Consequently, the multifunctional nanoplatform provides a potential strategy of synergetic chemotherapy and immunotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

A Multifunctional Biomimetic Nanoplatform for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PD‐1/PD‐L1 Axis

Zou

Liu

et al. 2018

Small

Self Cite

134

View full text Add to dashboard Cite

show abstract

“…A widely used porphyrin‐based Zr‐MOF (PCN‐224), PCN@FM was prepared by cloaking PCN‐224 with FM under ultrasound in ice bath . The synthesized PCN‐224 was observed by scanning electron microscopy (SEM, Figure S2, Supporting Information).…”

Section: Methodsmentioning

confidence: 99%

Expandable Immunotherapeutic Nanoplatforms Engineered from Cytomembranes of Hybrid Cells Derived from Cancer and Dendritic Cells

et al. 2019

View full text Add to dashboard Cite

Using the cytomembranes (FMs) of hybrid cells acquired from the fusion of cancer and dendritic cells (DCs), this study offers a biologically derived platform for the combination of immunotherapy and traditional oncotherapy approaches. Due to the immunoactivation implicated in the cellular fusion, FMs can effectively express whole cancer antigens and immunological co‐stimulatory molecules for robust immunotherapy. FMs share the tumor's self‐targeting character with the parent cancer cells. In bilateral tumor‐bearing mouse models, the FM‐coated nanophotosensitizer causes durable immunoresponse to inhibit the rebound of primary tumors post‐nanophotosensitizer‐induced photodynamic therapy (PDT). The FM‐induced immunotherapy displays ultrahigh antitumor effects even comparable to that of PDT. On the other hand, PDT toward primary tumors enhances the immunotherapy‐caused regression of the irradiation‐free distant tumors. Consequently, both the primary and the distant tumors are almost completely eliminated. This tumor‐specific immunotherapy‐based nanoplatform is potentially expandable to multiple tumor types and readily equipped with diverse functions owing to the flexible nanoparticle options.

show abstract

“…By combining PDT with drugs that are not hindered by hypoxia, more thorough tumor treatment can be achieved. In one example of dual PDT/chemotherapy, a porphyrinic metal organic framework (a PDT photosensitizer) was combined with tirapazamine (TPZ, a bioreactive chemotherapeutic) [73]. These agents were wrapped in membranes derived from 4T1 breast cancer cells, and the resultant NPs were delivered to mice bearing orthotopic 4T1 breast cancer tumors.…”

Section: Photodynamic Therapy Combined With Chemotherapy or Starvatiomentioning

confidence: 99%

“…Following irradiation, the porphyrinic metal organic frameworks produced ROS, leading to local hypoxia within the tumors, which accelerated the activation of TPZ for an enhanced chemotherapeutic effect. Because the treatment was activated only in the presence of light at the tumor site, negligible side effects were observed [73].…”

Section: Photodynamic Therapy Combined With Chemotherapy or Starvatiomentioning

confidence: 99%

Cancer Cell Membrane-Coated Nanoparticles for Cancer Management

Harris

Scully

Day

2019

Cancers

188

125

View full text Add to dashboard Cite

Cancer is a global health problem in need of transformative treatment solutions for improved patient outcomes. Many conventional treatments prove ineffective and produce undesirable side effects because they are incapable of targeting only cancer cells within tumors and metastases post administration. There is a desperate need for targeted therapies that can maximize treatment success and minimize toxicity. Nanoparticles (NPs) with tunable physicochemical properties have potential to meet the need for high precision cancer therapies. At the forefront of nanomedicine is biomimetic nanotechnology, which hides NPs from the immune system and provides superior targeting capabilities by cloaking NPs in cell-derived membranes. Cancer cell membranes expressing "markers of self" and "self-recognition molecules" can be removed from cancer cells and wrapped around a variety of NPs, providing homotypic targeting and circumventing the challenge of synthetically replicating natural cell surfaces. Compared to unwrapped NPs, cancer cell membrane-wrapped NPs (CCNPs) provide reduced accumulation in healthy tissues and higher accumulation in tumors and metastases. The unique biointerfacing capabilities of CCNPs enable their use as targeted nanovehicles for enhanced drug delivery, localized phototherapy, intensified imaging, or more potent immunotherapy. This review summarizes the state-of-the-art in CCNP technology and provides insight to the path forward for clinical implementation.

show abstract

Cancer cell membrane-coated biomimetic platform for tumor targeted photodynamic therapy and hypoxia-amplified bioreductive therapy

Cited by 238 publications

References 42 publications

A Multifunctional Biomimetic Nanoplatform for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PD‐1/PD‐L1 Axis

A Multifunctional Biomimetic Nanoplatform for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PD‐1/PD‐L1 Axis

Expandable Immunotherapeutic Nanoplatforms Engineered from Cytomembranes of Hybrid Cells Derived from Cancer and Dendritic Cells

Cancer Cell Membrane-Coated Nanoparticles for Cancer Management

Contact Info

Product

Resources

About